A Case of Favorable Responses after Gefitinib in a Patient with EGFR Mutated Adenosquamous Lung Carcinoma
Soonchunhyang Medical Science
; : 123-127, 2013.
Article
em En
| WPRIM
| ID: wpr-147411
Biblioteca responsável:
WPRO
ABSTRACT
In patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as first treatment option. Because adenosquamous carcinoma (ASC) is a rare histologic subtype, evidences about EGFR-TKIs as first treatment option for advanced ASC are lacking. We report a case of an advanced ASC patient with the EGFR mutation, who showed good responses during 4-month treatment with gefitinib. And we will review about a necessity of EGFR mutation test and efficacy of EGFR-TKIs in ASC patients from the recent studies.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Fosfotransferases
/
Carcinoma Adenoescamoso
/
Carcinoma Pulmonar de Células não Pequenas
/
Fator de Crescimento Epidérmico
/
Receptores ErbB
/
Pulmão
Limite:
Humans
Idioma:
En
Revista:
Soonchunhyang Medical Science
Ano de publicação:
2013
Tipo de documento:
Article